Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ALG-097558 DDI, Bioavailability, and Food Effect in Healthy Volunteers
NCT06945276Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ALG-097558 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity, Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration and 3 more. Started May 2025; status: completed.
02
Drugs
ALG-097558
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06945276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06945276.